

<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilities" xlink:href="vnda-20190930.xsd#AccountsPayableAndAccruedLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail" xlink:href="vnda-20190930.xsd#AccountsPayableAndAccruedLiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:href="vnda-20190930.xsd#AccountsPayableAndAccruedLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome" xlink:href="vnda-20190930.xsd#AccumulatedOtherComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail" xlink:href="vnda-20190930.xsd#AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail" xlink:href="vnda-20190930.xsd#AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:href="vnda-20190930.xsd#AccumulatedOtherComprehensiveIncomeTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentation" xlink:href="vnda-20190930.xsd#BusinessOrganizationAndPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentationDetail" xlink:href="vnda-20190930.xsd#BusinessOrganizationAndPresentationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:href="vnda-20190930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail" xlink:href="vnda-20190930.xsd#CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail" xlink:href="vnda-20190930.xsd#CommitmentsAndContingenciesFanaptAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail" xlink:href="vnda-20190930.xsd#CommitmentsAndContingenciesHetliozAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesResearchAndDevelopmentAndMarketingAgreementsDetails" xlink:href="vnda-20190930.xsd#CommitmentsAndContingenciesResearchAndDevelopmentAndMarketingAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesSummaryOfNoncanellableLongTermContractualCashObligationsDetail" xlink:href="vnda-20190930.xsd#CommitmentsAndContingenciesSummaryOfNoncanellableLongTermContractualCashObligationsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTables" xlink:href="vnda-20190930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" xlink:href="vnda-20190930.xsd#CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesVqw765AdditionalInformationDetail" xlink:href="vnda-20190930.xsd#CommitmentsAndContingenciesVqw765AdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="vnda-20190930.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="vnda-20190930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="vnda-20190930.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:href="vnda-20190930.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="vnda-20190930.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="vnda-20190930.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:href="vnda-20190930.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsPerShare" xlink:href="vnda-20190930.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail" xlink:href="vnda-20190930.xsd#EarningsPerShareDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsPerShareTables" xlink:href="vnda-20190930.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurements" xlink:href="vnda-20190930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="vnda-20190930.xsd#FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxes" xlink:href="vnda-20190930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesDetails" xlink:href="vnda-20190930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssets" xlink:href="vnda-20190930.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsAdditionalInformationDetail" xlink:href="vnda-20190930.xsd#IntangibleAssetsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail" xlink:href="vnda-20190930.xsd#IntangibleAssetsFanaptAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail" xlink:href="vnda-20190930.xsd#IntangibleAssetsHetliozAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail" xlink:href="vnda-20190930.xsd#IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail" xlink:href="vnda-20190930.xsd#IntangibleAssetsSummaryOfIntangibleAssetsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables" xlink:href="vnda-20190930.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/Inventory" xlink:href="vnda-20190930.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/InventoryDetail" xlink:href="vnda-20190930.xsd#InventoryDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/InventoryTables" xlink:href="vnda-20190930.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/Leases" xlink:href="vnda-20190930.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" xlink:href="vnda-20190930.xsd#LeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsAndLiabilitiesDetails" xlink:href="vnda-20190930.xsd#LeasesLeaseAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails" xlink:href="vnda-20190930.xsd#LeasesMaturitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetailsCalc2" xlink:href="vnda-20190930.xsd#LeasesMaturitiesDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesUnderAsc840Details" xlink:href="vnda-20190930.xsd#LeasesMaturitiesUnderAsc840Details" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesTables" xlink:href="vnda-20190930.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LegalMatters" xlink:href="vnda-20190930.xsd#LegalMatters" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecurities" xlink:href="vnda-20190930.xsd#MarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" xlink:href="vnda-20190930.xsd#MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables" xlink:href="vnda-20190930.xsd#MarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PublicOfferingOfCommonStock" xlink:href="vnda-20190930.xsd#PublicOfferingOfCommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PublicOfferingOfCommonStockDetail" xlink:href="vnda-20190930.xsd#PublicOfferingOfCommonStockDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensation" xlink:href="vnda-20190930.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail" xlink:href="vnda-20190930.xsd#StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail" xlink:href="vnda-20190930.xsd#StockBasedCompensationRsuAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail" xlink:href="vnda-20190930.xsd#StockBasedCompensationStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" xlink:href="vnda-20190930.xsd#StockBasedCompensationStockOptionAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" xlink:href="vnda-20190930.xsd#StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" xlink:href="vnda-20190930.xsd#StockBasedCompensationSummaryOfRsuActivityPlanDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables" xlink:href="vnda-20190930.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" xlink:href="vnda-20190930.xsd#StockBasedCompensationTotalStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="vnda-20190930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="vnda-20190930.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail" xlink:href="vnda-20190930.xsd#SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="vnda-20190930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:href="vnda-20190930.xsd#SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesSupplementalCashFlowsInformationDetails" xlink:href="vnda-20190930.xsd#SummaryOfSignificantAccountingPoliciesSupplementalCashFlowsInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="vnda-20190930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/Tables" xlink:href="vnda-20190930.xsd#Tables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_81D8052BF9BF54CD959036EC55C6264F" xlink:type="locator" />
    <link:loc xlink:href="vnda-20190930.xsd#vnda_AccruedResearchAndDevelopmentExpense" xlink:label="loc_vnda_AccruedResearchAndDevelopmentExpense_3DF2801B4526516D9B5B2CFFCA97CD24" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_81D8052BF9BF54CD959036EC55C6264F" xlink:to="loc_vnda_AccruedResearchAndDevelopmentExpense_3DF2801B4526516D9B5B2CFFCA97CD24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_C25A868B09AC5F33993C16EA0AD545A6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_81D8052BF9BF54CD959036EC55C6264F" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_C25A868B09AC5F33993C16EA0AD545A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_085E66B359B853FE9BC3AAB42307D7D8" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_81D8052BF9BF54CD959036EC55C6264F" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_085E66B359B853FE9BC3AAB42307D7D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_995020C465A15685AD24E7A4B9B84561" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_81D8052BF9BF54CD959036EC55C6264F" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_995020C465A15685AD24E7A4B9B84561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4F1ACDF5BA0359599C7333C3C2CC03B8" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_81D8052BF9BF54CD959036EC55C6264F" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4F1ACDF5BA0359599C7333C3C2CC03B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_AB9004609D145E5183A0F4F39F883206" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_81D8052BF9BF54CD959036EC55C6264F" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_AB9004609D145E5183A0F4F39F883206" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F35D9628725D5E51B52F8F46B72F82FE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_B2D03409D1F25F8E8B46D2AE3F4027D2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F35D9628725D5E51B52F8F46B72F82FE" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_B2D03409D1F25F8E8B46D2AE3F4027D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8AB3D674BB465EFE8BDC129A621D44DE" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F35D9628725D5E51B52F8F46B72F82FE" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8AB3D674BB465EFE8BDC129A621D44DE" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesResearchAndDevelopmentAndMarketingAgreementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesSummaryOfNoncanellableLongTermContractualCashObligationsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_AC3CF095E0255725B780B4EC4A85A022" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_4599CAE267705CAB98054E2BDDCAFADC" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_AC3CF095E0255725B780B4EC4A85A022" xlink:to="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_4599CAE267705CAB98054E2BDDCAFADC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_9132812DD10F5A9FB1D7A01D4781505D" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_AC3CF095E0255725B780B4EC4A85A022" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_9132812DD10F5A9FB1D7A01D4781505D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_9A9210E72139535E8E19D5788EB37E6B" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_AC3CF095E0255725B780B4EC4A85A022" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_9A9210E72139535E8E19D5788EB37E6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligationDueInFourthYear" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_248311F2F25D5DF1BF8E91ADB09F603C" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_AC3CF095E0255725B780B4EC4A85A022" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_248311F2F25D5DF1BF8E91ADB09F603C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligationDueInFifthYear" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear_4084966EE3675F1A810E7DC0CD9FF67C" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_AC3CF095E0255725B780B4EC4A85A022" xlink:to="loc_us-gaap_PurchaseObligationDueInFifthYear_4084966EE3675F1A810E7DC0CD9FF67C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligationDueAfterFifthYear" xlink:label="loc_us-gaap_PurchaseObligationDueAfterFifthYear_9D0412C1A4A05FF994A048ACE16C3DD1" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_AC3CF095E0255725B780B4EC4A85A022" xlink:to="loc_us-gaap_PurchaseObligationDueAfterFifthYear_9D0412C1A4A05FF994A048ACE16C3DD1" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesVqw765AdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d32a2417-a96e-df92-8909-70df29d31528" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d32a2417-a96e-df92-8909-70df29d31528" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_52f5671e-53e6-6055-795e-6bd414fd86c2" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_52f5671e-53e6-6055-795e-6bd414fd86c2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5be77b8d-fe95-a009-6655-0f33965794f2" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5be77b8d-fe95-a009-6655-0f33965794f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_5ee94de1-09b5-a281-d50f-420352002a69" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_5ee94de1-09b5-a281-d50f-420352002a69" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190930.xsd#vnda_InventoryAndOtherNonCurrent" xlink:label="loc_vnda_InventoryAndOtherNonCurrent_9c718b66-72e6-5807-3420-ddb163d8932c" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_vnda_InventoryAndOtherNonCurrent_9c718b66-72e6-5807-3420-ddb163d8932c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_47ecca60-0dc8-25b2-6295-72031a21e0cb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_47ecca60-0dc8-25b2-6295-72031a21e0cb" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190930.xsd#vnda_ProductRevenueAllowancesCurrent" xlink:label="loc_vnda_ProductRevenueAllowancesCurrent_2596f15e-7a0e-e20c-8c56-ddb1639e220c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_vnda_ProductRevenueAllowancesCurrent_2596f15e-7a0e-e20c-8c56-ddb1639e220c" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190930.xsd#vnda_MilestoneObligationUnderLicenseAgreementCurrent" xlink:label="loc_vnda_MilestoneObligationUnderLicenseAgreementCurrent_e547cde8-3f77-e786-d9a0-ddb1640353ea" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_vnda_MilestoneObligationUnderLicenseAgreementCurrent_e547cde8-3f77-e786-d9a0-ddb1640353ea" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df284507-8ac7-eed1-41db-05e81b70be6d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df284507-8ac7-eed1-41db-05e81b70be6d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_38b416a4-4707-fba3-1084-9b8a37fd745a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_Depreciation_38b416a4-4707-fba3-1084-9b8a37fd745a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_2e4e7778-759c-bb90-4954-46dd703615e0" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_2e4e7778-759c-bb90-4954-46dd703615e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_afd0f625-a29a-3806-bad0-ad0ca19e7015" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_afd0f625-a29a-3806-bad0-ad0ca19e7015" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_29b0a481-c653-23c1-27cf-114dadcce1af" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_29b0a481-c653-23c1-27cf-114dadcce1af" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_334f1d33-7cae-7fd2-9d83-bb387fc2f3dd" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_334f1d33-7cae-7fd2-9d83-bb387fc2f3dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_91c354d1-d18f-051e-80cb-f13c01058b9d" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_91c354d1-d18f-051e-80cb-f13c01058b9d" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190930.xsd#vnda_IncreaseDecreaseProductRevenueAllowances" xlink:label="loc_vnda_IncreaseDecreaseProductRevenueAllowances_2dd495cd-1831-0957-7282-ddb163d69ef1" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_vnda_IncreaseDecreaseProductRevenueAllowances_2dd495cd-1831-0957-7282-ddb163d69ef1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5a6cca43-79c5-34f3-6172-5859b13486b1" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5a6cca43-79c5-34f3-6172-5859b13486b1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_c4aa0718-f1b7-8481-8382-216f94e41c89" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_c4aa0718-f1b7-8481-8382-216f94e41c89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_1e99261d-1af1-2d77-636d-890a4a9c4511" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_1e99261d-1af1-2d77-636d-890a4a9c4511" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6ec8bc8e-bcd9-36ad-d8ae-2c2fa1dfd920" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6ec8bc8e-bcd9-36ad-d8ae-2c2fa1dfd920" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_706d3cc5-3df5-1e1a-5067-c02728407eb6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_706d3cc5-3df5-1e1a-5067-c02728407eb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_714a30d1-878f-1497-8ad1-4b1e113da228" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_714a30d1-878f-1497-8ad1-4b1e113da228" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e68ce304-18e4-96c0-3260-363a872863db" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e68ce304-18e4-96c0-3260-363a872863db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_7cf8d201-6043-c5b4-c413-80aeee19ca82" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e68ce304-18e4-96c0-3260-363a872863db" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_7cf8d201-6043-c5b4-c413-80aeee19ca82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_9e072cec-4fcb-d083-f0ab-2b83cce1f9d0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e68ce304-18e4-96c0-3260-363a872863db" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_9e072cec-4fcb-d083-f0ab-2b83cce1f9d0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_aa6d7695-3c9c-a820-1c3c-0e977db4a781" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e68ce304-18e4-96c0-3260-363a872863db" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_aa6d7695-3c9c-a820-1c3c-0e977db4a781" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:to="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_435f940b-a471-4122-5132-a245458f6913" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_Revenues_435f940b-a471-4122-5132-a245458f6913" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c604cfe-da19-5194-72b6-98be0130cfb7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_435f940b-a471-4122-5132-a245458f6913" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c604cfe-da19-5194-72b6-98be0130cfb7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsSoldExcludingDepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_CostOfGoodsSoldExcludingDepreciationDepletionAndAmortization_614698d5-cd0e-e341-3061-9d4305fb3673" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_CostOfGoodsSoldExcludingDepreciationDepletionAndAmortization_614698d5-cd0e-e341-3061-9d4305fb3673" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_693c47dd-e6fa-9c85-6a65-7baa26f76b5e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_693c47dd-e6fa-9c85-6a65-7baa26f76b5e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_afd0f625-a29a-3806-bad0-ad0ca19e7015" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_afd0f625-a29a-3806-bad0-ad0ca19e7015" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome_bb610d99-851f-be70-f405-1d0649f0a727" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:to="loc_us-gaap_OtherIncome_bb610d99-851f-be70-f405-1d0649f0a727" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21ce4f2f-397c-6c02-8635-7c94146a06a0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2dd9a981-e559-d141-f1c2-4db79f71a7ef" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21ce4f2f-397c-6c02-8635-7c94146a06a0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2dd9a981-e559-d141-f1c2-4db79f71a7ef" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d342f32b-4cc6-0bef-3743-616005090121" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21ce4f2f-397c-6c02-8635-7c94146a06a0" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d342f32b-4cc6-0bef-3743-616005090121" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssets" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_228E3BB23A1C599F8337597105A65779" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_23E2DD96BB8058238CE572DD7311DFAA" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_228E3BB23A1C599F8337597105A65779" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_23E2DD96BB8058238CE572DD7311DFAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_FF7D1A304CBE51D2A132F996AD52D6C8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_228E3BB23A1C599F8337597105A65779" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_FF7D1A304CBE51D2A132F996AD52D6C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_89A6D64F9E4D568AB4AD7A2D44DC8497" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_228E3BB23A1C599F8337597105A65779" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_89A6D64F9E4D568AB4AD7A2D44DC8497" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_597D67FCF45F5142A78830E363A339A9" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_228E3BB23A1C599F8337597105A65779" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_597D67FCF45F5142A78830E363A339A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_7238260643CF5CADAECBC1E74FF53760" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_228E3BB23A1C599F8337597105A65779" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_7238260643CF5CADAECBC1E74FF53760" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_0B7535A1993F58AB87FD669BA82E3BFA" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_228E3BB23A1C599F8337597105A65779" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_0B7535A1993F58AB87FD669BA82E3BFA" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_228E3BB23A1C599F8337597105A65779" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_96EDA9A0F8EB505389300088A1ED74ED" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_228E3BB23A1C599F8337597105A65779" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_96EDA9A0F8EB505389300088A1ED74ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_29389CF357E7509299AE32600CEF301F" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_228E3BB23A1C599F8337597105A65779" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_29389CF357E7509299AE32600CEF301F" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/InventoryDetail" xlink:type="extended">
    <link:loc xlink:href="vnda-20190930.xsd#vnda_Inventory" xlink:label="loc_vnda_Inventory_8D86B2EE0B3C509CB13D6895B88427F3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_B870296AAF9B5823AA79DAF459CE3F64" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vnda_Inventory_8D86B2EE0B3C509CB13D6895B88427F3" xlink:to="loc_us-gaap_InventoryNoncurrent_B870296AAF9B5823AA79DAF459CE3F64" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190930.xsd#vnda_InventoryRawMaterialsNetOfReservesNonCurrent" xlink:label="loc_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_5B12F5E631075B409B844C3864489F53" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNoncurrent_B870296AAF9B5823AA79DAF459CE3F64" xlink:to="loc_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_5B12F5E631075B409B844C3864489F53" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190930.xsd#vnda_InventoryWorkInProcessNetOfReservesNonCurrent" xlink:label="loc_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_3BFA6E8A99705A5AA6FF1CAB902516AD" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNoncurrent_B870296AAF9B5823AA79DAF459CE3F64" xlink:to="loc_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_3BFA6E8A99705A5AA6FF1CAB902516AD" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190930.xsd#vnda_InventoryFinishedGoodsNetOfReservesNonCurrent" xlink:label="loc_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_E0F7967A116C5AB68B02D58DE2900411" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNoncurrent_B870296AAF9B5823AA79DAF459CE3F64" xlink:to="loc_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_E0F7967A116C5AB68B02D58DE2900411" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_A166F30F2CD05E30A51D78B061B4B219" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vnda_Inventory_8D86B2EE0B3C509CB13D6895B88427F3" xlink:to="loc_us-gaap_InventoryNet_A166F30F2CD05E30A51D78B061B4B219" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_A4E9EB7160B55DC38EF5609FBF58105D" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_A166F30F2CD05E30A51D78B061B4B219" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_A4E9EB7160B55DC38EF5609FBF58105D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_F0E884568AFB5301BA8032FC71BB1608" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_A166F30F2CD05E30A51D78B061B4B219" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_F0E884568AFB5301BA8032FC71BB1608" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/Leases" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_41784c6f-4555-af92-3354-8f8701c77f60" xlink:type="locator" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d0e3c4ab-df94-52c6-3761-ce2ed0f2f507" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d0e3c4ab-df94-52c6-3761-ce2ed0f2f507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e0f20176-305e-e29f-ab09-584aea596901" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e0f20176-305e-e29f-ab09-584aea596901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8e35e675-3955-0e95-1b9c-d08dd410962e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8e35e675-3955-0e95-1b9c-d08dd410962e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_852d78fc-d4b9-e5fb-fd5a-9da7d3d49669" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_852d78fc-d4b9-e5fb-fd5a-9da7d3d49669" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7a6864a2-d55e-24e7-17f1-75d5cad038ee" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7a6864a2-d55e-24e7-17f1-75d5cad038ee" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a8c7556a-9f4c-b4fb-2e42-b21cf84287a7" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a8c7556a-9f4c-b4fb-2e42-b21cf84287a7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_41784c6f-4555-af92-3354-8f8701c77f60" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_09c9f846-159b-1776-fceb-d1cad0eb94ab" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_41784c6f-4555-af92-3354-8f8701c77f60" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_09c9f846-159b-1776-fceb-d1cad0eb94ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_41784c6f-4555-af92-3354-8f8701c77f60" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_D2D9C90F7D0C99F27AB5D0779AD60843_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D2D9C90F7D0C99F27AB5D0779AD60843_dba432e7-eec4-e0dc-718d-f46fe263fe47" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_D2D9C90F7D0C99F27AB5D0779AD60843_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D2D9C90F7D0C99F27AB5D0779AD60843_dba432e7-eec4-e0dc-718d-f46fe263fe47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_D2D9C90F7D0C99F27AB5D0779AD60843_41784c6f-4555-af92-3354-8f8701c77f60" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_D2D9C90F7D0C99F27AB5D0779AD60843_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_OperatingLeaseLiability_D2D9C90F7D0C99F27AB5D0779AD60843_41784c6f-4555-af92-3354-8f8701c77f60" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesUnderAsc840Details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_7763727B919452E3ADFE4B5AC34828F4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_9F9D7B9F9373540E8F87A61BED388E7C" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_7763727B919452E3ADFE4B5AC34828F4" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_9F9D7B9F9373540E8F87A61BED388E7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_87AB5DB67C7154FAA556ACD7758C4EE2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_7763727B919452E3ADFE4B5AC34828F4" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_87AB5DB67C7154FAA556ACD7758C4EE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_4B77CD66A7C95C9CA0710D0B5C2B4753" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_7763727B919452E3ADFE4B5AC34828F4" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_4B77CD66A7C95C9CA0710D0B5C2B4753" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_BBD107C6A71752F5A2D8CFAD308BB5A8" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_7763727B919452E3ADFE4B5AC34828F4" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_BBD107C6A71752F5A2D8CFAD308BB5A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_C5236E34923659CAB8D45C6B2B5648E9" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_7763727B919452E3ADFE4B5AC34828F4" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_C5236E34923659CAB8D45C6B2B5648E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_9FA1136643B559428D181392569D6D1B" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_7763727B919452E3ADFE4B5AC34828F4" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_9FA1136643B559428D181392569D6D1B" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/LegalMatters" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecurities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d23fa7e-7f76-6507-b72f-382f81b88e34" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d23fa7e-7f76-6507-b72f-382f81b88e34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e0f935d0-20e2-15fc-55a1-79c116fbc07c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e0f935d0-20e2-15fc-55a1-79c116fbc07c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/PublicOfferingOfCommonStock" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/PublicOfferingOfCommonStockDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesSupplementalCashFlowsInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ce4b89e-fa52-7101-5bea-622168a4559a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ce4b89e-fa52-7101-5bea-622168a4559a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_61d6663d-71dc-4159-c90b-9591805979c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ce4b89e-fa52-7101-5bea-622168a4559a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_61d6663d-71dc-4159-c90b-9591805979c3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/Tables" xlink:type="extended" />
</link:linkbase>